Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Has results × ALK+ Advanced NSCLC × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 258 Carcinoma, Non-Small-Cell Lung 182 Prostatic Neoplasms 138 Neoplasms 136 Multiple Myeloma 104 Neoplasm Metastasis 74 Colorectal Neoplasms 71 Leukemia, Myeloid, Acute 65 Parkinson Disease 4, Autosomal Dominant Lewy Body 58 Lung Neoplasms 58 Lymphoma, Non-Hodgkin 57 Melanoma 56 Lymphoma, Follicular 56 Leukemia, Lymphocytic, Chronic, B-Cell 55 Papillomavirus Infections 54 Leukemia 50 Lymphoma 48 Precursor Cell Lymphoblastic Leukemia-Lymphoma 46 Uterine Cervical Neoplasms 45 Carcinoma, Renal Cell 43 Ovarian Neoplasms 42 Pain 41 Carcinoma, Hepatocellular 40 Recurrence 39 Keratosis, Actinic 39 Head and Neck Neoplasms 33 Lymphoma, Large B-Cell, Diffuse 32 Pancreatic Neoplasms 30 Urinary Bladder Neoplasms 29 Stomach Neoplasms 29

Interventions

brigatinib 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03596866 2025-09-12

ALTA-3

Takeda

Phase 3 Completed

248 enrolled 20 charts

ALK+ Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡